Commentary

Video

Dr. Dmochowski on tibial nerve stimulation as an earlier line of therapy for OAB

Author(s):

Urology Times staff
Conference|AUA

Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the Revi System, specifically touching on how the device may be used as a potential earlier line of therapy for patients with OAB.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Roger R. Dmochowski, MD, MMHC, highlights the FDA approval of the BlueWind Revi System, specifically touching on how the device is being recognized as a potential earlier line of therapy for patients with overactive bladder (OAB). Dmochowski is the chief medical officer at BlueWind Medical as well as a professor of urology, gynecology, and surgery and Vanderbilt University Medical Center in Nashville, Tennesee.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Kevin T. McVary, MD, FACS, answers a question during a Zoom video interview
      Kevin T. McVary, MD, FACS, discusses the expanded label for Rezum in BPH
      Amy Krambeck, MD, on considerations for building clinical programs in endourology
      Amy Krambeck, MD, on considerations for building clinical programs in endourology
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      David Stanley, MD, on current trends in the management of kidney stones
      David Stanley, MD, on current trends in the management of kidney stones
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
      Roger Dmochowski, MD, on quality-of-life outcomes with the Revi System
      Anne Schuckman, MD, highlights promising new developments in NMIBC
      Anne Schuckman, MD, highlights promising new developments in NMIBC
      Related Content
      Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
      June 9th 2025

      Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

      Hannah Clarke
      The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC
      June 5th 2025

      Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

      Hannah Clarke
      According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
      Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
      May 1st 2025

      Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

      Amy M. Pearlman, MD
      Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
      Amy L. Shaver, PhD, PharmD, MPH
      June 5th 2025

      GLP-1 agonist use is rising in men with prostate cancer

      Benjamin P. Saylor
      In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
      Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
      June 4th 2025

      Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

      Hannah Clarke
      “AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
      © 2025 MJH Life Sciences

      All rights reserved.